This has been confirmed by data obtained in the present study, showing that no more that 8% of BC, OC or PC cancer show BRCA1/2 mutations even in the group of early onset cases.; that the use of multi-gene hereditary cancer panels increases the possibility to identify individuals with cancer predisposing gene variants (Shin et al., 2020; Hu et al., 2021). The gene discussed is BRCA1; the disease is pachyonychia congenita.